What's Happening?
Symeres, a Netherlands-based contract research, development, and manufacturing organization (CRDMO), has expanded its spray drying capabilities at its Cranbury, New Jersey site. This expansion aims to support the formulation development of poorly soluble
small-molecule drug candidates. The enhanced capabilities will aid in bioavailability enhancement strategies, including amorphous solid dispersions and solubility optimization. The investment strengthens Symeres' integrated CMC offering, allowing for seamless progression from early formulation screening to clinical-ready material, thereby reducing tech-transfer risks and accelerating decision-making.
Why It's Important?
The expansion of Symeres' spray drying capabilities is a significant development in the pharmaceutical industry, particularly for companies dealing with complex drug formulations. By enhancing its facilities, Symeres can better support the development of challenging drug candidates, potentially leading to more effective treatments reaching the market faster. This move reflects the growing demand for advanced formulation technologies to address the solubility and bioavailability challenges of modern drug candidates. It also positions Symeres as a key player in the pharmaceutical development landscape, offering comprehensive solutions to its clients.
